| Name | Title | Contact Details |
|---|
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
Clintech Research is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highline Sciences is a specialized, full-service CRO and consultancy founded from within an oncology biotech to provide a better solution. We understand the gap between what you need and what you get from a traditional CRO and we’re here to improve the...
Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel`s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin`s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.